Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Novel Insights into Cannabinoid Receptors, Molecular Targets, and Therapeutic Potentials"
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell Signaling".
Deadline for manuscript submissions: 30 September 2023 | Viewed by 19071
Special Issue Editor
Interests: cannabinoid receptors; novel cannabinoid targets; cannabinoid signaling; cannabinoid therapeutic potentials
Special Issue Information
Cannabis has been used as a remedy for illness for centuries in various cultures. Recently, there has been a renewed interest in the uses of cannabis and cannabinoids for medicinal purposes, due to improved legal status in medical cannabis and the advances in cannabinoid research. Cannabinoids are composed of three categories, including phytocannabinoids (the active chemical components of cannabis), endocannabinoids (the cannabinoid-like substances in our body), and synthetic cannabinoids (the cannabinoids prepared in the laboratory). Cannabinoids exert their effects through multiple receptors, targets and signaling pathways. In addition to CB1 and CB2, two well-established cannabinoid receptors, there are numerous molecular targets for cannabinoids, e.g., G-protein-coupled receptors (GPR55, GPR18, GPR3/GPR6/GPR12), transient receptor potential (TRPV) channels, and peroxisome proliferator-activated (PPAR) receptors. These cannabinoid receptors and molecular targets play essential roles for the effects of cannabinoids in health and disease. In addition, they are underscoring the mechanisms of actions for the potential therapeutic effects of a variety of cannabinoids. Recently, there have been tremendous advances in our understanding of these receptors and molecular targets, as well as their implications in the therapeutic potentials of cannabinoids.
The emphasis of this Special Issue is on the recent advances in our knowledge of cannabinoid receptors, molecular targets, and signaling pathways in the context of physiological/pathological conditions, and cannabinoid therapeutic potentials. Review articles summarizing recent discoveries, and original research articles of both basic and clinical studies are welcome.
We look forward to your important contributions.
Dr. Zhao-Hui Song
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Cannabinoid receptor
- Molecular target
- Signal transduction
- Therapeutic potentials
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: The early chronic administration of Cannabidivarin prevents the neurobehavioral abnormalities of the Fmr1-KO mouse model for Fragile X syndrome
Authors: Marika Premoli1,2 *, William Fyke1,3*, Luigi Bellocchio4, Valerie Lemaire1, Marie Wolley-Roberts5, Wim E. Crusio1, Bruno Bontempi1 and Susanna Pietropaolo1
Affiliation: 1 Univ. Bordeaux, CNRS, EPHE, INCIA, UMR 5287, F-33000 Bordeaux, France 2University of Brescia, Department of Molecular and Translational Medicine, Brescia, Italy 3Graduate Program in Neural and Behavioral Science, SUNY Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, NY 11203, USA 4University of Bordeaux, INSERM, U1215, NeuroCentre Magendie, Group Endocannabinoids and Neuroadaptation, Bordeaux 33077, France. 5GW GW Research Ltd, Cambridge, UK
Abstract: Converging lines of evidence have recently highlighted the therapeutic potential of phytocannabinoids, such as Cannabidivarin (CBDV), in several neurodevelopmental pathologies. Nonetheless, the therapeutic value of CBDV has never been tested in Fragile X syndrome (FXS), i.e., a major developmental monogenic disorder. Here we characterized the neurobehavioral effects of CBDV in the Fmr1-KO mouse model of FXS. CBDV was administered intraperitoneally at the daily doses of 20 and 100 mg/kg, either sub-chronically during adulthood (Study 1) or chronically at adolescence (Study 2). Behavioral tests assessing FXS-like abnormalities including anxiety, locomotor, cognitive, social and sensory alterations were performed. Inflammatory (e.g., interleukins) and plasticity (e.g., brain derived neurotrophic factor) markers were also assessed in cortical and hippocampal brain areas. When administered during adulthood (Study 1), CBDV exerted marginal and exclusively behavioral effects, i.e., rescuing at the dose of 20 mg/Kg only the acoustic hyper-responsiveness displayed by Fmr1-KO mice. When administered during adolescence (Study 2), chronic CBDV at both doses rescued the cognitive, social and acoustic alterations of mutant mice and exerted several brain effects in both Fmr1-KO and WT animals. These results support the therapeutic potential of CBDV for treating FXS, highlighting the relevance of the duration and timing of the treatments.